Management of Tear Trough with Hyaluronic Acid Fillers: A Clinical-Practice Dual Approach

Abstract

Introduction

Tear trough deformity (TTD) is currently a major concern for many individuals that seek periorbital rejuvenation. Among the different options currently available for treating TTD, hyaluronic acid (HA) filler injections have become increasingly popular.

Purpose

To provide a dual approach, direct and indirect strategies for treating TTD with HA fillers according to patient facial structure.

Methods

The current paper combined the authors’ experience with the currently available scientific evidence.

Results

The current study presents the authors clinical experience regarding TTD treatment and serves as a guide on the best therapeutic approach with HA fillers. For achieving good aesthetic outcomes, especially in TTD, it is crucial to have a detailed understanding of both facial anatomy and the individual characteristics of the HA fillers. Proper management of full-face facial rejuvenation should have into consideration three main pillars: structure, contour, and refinement.

Conclusion

Treatment of TTD should be addressed from a comprehensive perspective, including potential lack of structural support, as well as interventions on the dynamic processes involved in the problem. Additionally, HA fillers can be used to modulate mechanically muscle movement by either facilitating their action or decreasing contractility by reducing their movement. Clinicians can benefit from ongoing guidance on the use of these products in order to tailor and optimize treatments to patient’s requirements. Although HA filler injections have low rates of side effects, TTD was listed as the most challenging area to treat with HA. Therefore, TTD treatment should be performed only by well-trained and experienced specialists.

Introduction

Periorbital lipoatrophy may be defined as a natural consequence of the anatomic attachments of the periorbital tissues.¹ It consists of a physiological process of supraperiosteal and subcutaneous fat loss that is noticeable as a result of inherited anatomical differences and aging.¹

Despite being of an important cosmetic concern, the exact etiology of the tear trough deformity (TTD) has not been well defined. However, different factors, such as gender (there are differences between men and women), congenital or age-related maxillary hypoplasia, laxity of the retaining ligaments of the periorbital area, cutaneous elastosis, structural changes in deep and/or superficial fat compartments, and a certain genetic predisposition have been proposed.^1–3

Multiple classification systems have been introduced to provide an objective means of evaluating the TTD and to aid the aesthetic medicine specialists in choosing appropriate treatment options.^4–8

Over the last several years, there has been considerable interest in nonsurgical treatment of the TTD using injectable products, such as hyaluronic acid (HA).⁹ Among the different therapeutic strategies, the MD Codes^® (Codes) represent specific anatomical subunits for injection of HA fillers.¹⁰ Additionally, HA fillers can be used to modulate mechanically muscle movement by either facilitating their action, via a lever or pulley effect, or decreasing contractility by reducing their movement.¹¹

The purpose of this paper is to provide two different treatment strategies for addressing tear trough deformity, with HA fillers, depending on patient’s facial structure.

Methods

The current study presents the clinical experience of the authors regarding TTD treatment, as well as an overview of the current evidence.

Patients signed written informed consent before treatment. Patients were fully informed about procedure, including side effects and potential complications. All procedures were carried out in accordance with the tenets of the Declaration of Helsinki. Study protocol was approved by the ethics committee of Instituto Médico Miramar.

Classification of TTD

Different classification systems have been proposed with the purpose of providing an objective method for assessing the TTD and selecting the best treatment options.^4–8

Barton et al,⁴ in an effort to analyze objectively their postoperative results, proposed a grading system based on anatomic analysis (Table 1).

Table 1.

Tear Trough Deformity Classification Systems.

Barton et al4	Hirmand5	Belhaouari et al7
Grade 0: Absence of medial or lateral lines demarcating the arcus marginalis or the orbital rim and a smooth, youthful contour without a transition zone at the orbit-cheek junction. Grade I: Mild, subtle presence of a medial line or shadow; smooth lateral transition of lid-cheek junction. Grade II: Moderate prominence of a visible demarcation of the lid-cheek junction, extending from medial to lateral. Grade III: Severe demarcation of the orbit-cheek junction, with an obvious step between the orbit and the cheek.	● Class I patients have volume loss limited medially to the tear trough. These patients can also have mild flattening extending to the central cheek. ● Class II patients exhibit volume loss in the lateral orbital area in addition to the medial orbit, and they may have moderate volume deficiency in the medial cheek and flattening of the central upper cheek. ● Class III patients present with a full depression circumferentially along the orbital rim, medial to lateral.	● Stage 1A: insufficient volume without ptosis ● Stage 1B: insufficient volume with ptosis ● Stage 2A: normal volume without ptosis ● Stage 2B: normal volume with ptosis ● Stage 3A: Increased volume without ptosis ● Stage 3B: Increased volume with ptosis.

Note: Data from these studies.^4,5,7

Hirmand proposed a classification system of the TTD based on clinical evaluation. According to this classification, the TTD might be addressed into three different types: Class I, II, and III (Table 1, Figure 1).⁵

Figure 1.

Hirmand classification of tear trough deformity. Data from Hirmand.⁵

There are currently two classification systems that evaluate the type of TTD and guide us on the best therapeutic approach with HA fillers.^4,7

Belhaouari et al⁷ proposed a classification that integrated both the semiological analysis and the therapeutic strategy (Tables 1 and 2). According to this classification, the TTD might be addressed into two ways: Direct one, which is indicated in the stages 2A and 3A; and an Indirect one that was proposed for the stages 1A, 1B, 2B, and 3B.^7,8

Table 2.

Belhaouari et al⁹ Tear Trough Classification System According to the Volume and the Ptosis with the Treatment Strategy with Hyaluronic Acid Filler

Tear Trough Classification System and Treatment Strategy

Stage 1A: Characteristic: Insufficient volume without ptosis. Treatment: Indirect approach (VYC-17.5L/VYC-20L) Stage 1B: Characteristics: Insufficient volume with ptosis. Treatment: Indirect approach (VYC-17.5L+VYC-20L ± VYC-15L) Stage 2A: Characteristics: Normal volume without ptosis. Treatment: Direct approach (VYC-15L) Stage 2B: Characteristics: Normal volume with ptosis. Treatment: Indirect approach (VYC-17.5L+VYC-20L ± VYC-15L) Stage 3A: Characteristics: Increased volume without ptosis. Treatment: Direct approach (VYC-15L) Stage 3B: Characteristics: Increased volume with ptosis. Treatment: Indirect approach (±VYC-17.5L+VYC-20L+ VYC-15L)

Abbrevaition: VYC, Vycross technology.

Classification systems are mainly based on anatomic analysis (Figure 1, Tables 1 and 2).

Treatment

Treatment strategy is based on the MD Codes^®, which were developed by Mauricio de Maio.^10,11

Myomodulation makes reference to the mechanic effect of HA on muscle function.^10–12 It is based on myotatic reflex, which causes muscle contraction after the muscle is stretched.^10–12 According to this theory, if there is a structural deficiency (either congenital or aging-related) and muscle contraction is weakened, HA filler placed under the muscle provides support and improves tensile strength by increasing distance between the origin and insertion, which increases mechanical advantage and facilitates the action of the muscle.^10–12 On the contrary, if the muscle action is excessive, injecting HA filler above the muscle or directly into or beneath the muscle near its origin or insertion creates a mechanical obstacle to the muscle action.^10–12

An overview of the action of HA fillers on the action of the different facial muscles is summarized in Figure 2. Additionally, Table 3 shows the mechanic myomodulation effect with HA filler on the different treatment points.

Figure 2.

Overview of the hyaluronic acid (HA) injectable filler on the muscle activity. Data from de Maio.¹¹ Image courtesy from and reprinted with permission from Allergan plc, Dublin, Ireland.

Abbreviation: N, nasalis; LAN, levator labii superioris alaeque nasi; LLS, levator labii superioris; LAO, levator anguli oris; ZMj, zygomaticus major; ZMi, zygomaticus minor; DSN, depressor septi nasi; DAO, depressor anguli oris; DLI, depressor labi inferiores; B, buccinator; R, risorius; PL, plastisma; OO, orbicularis oris; M, mentalis.

Table 3.

Mechanic Myomodulation Effect with Hyaluronic Acid (HA) Filler on the Different Treatment Points.

Treated Point	Location	Action
T1	Under	To increase tightening in temporal-orbicular and temporal-cutaneous true retaining ligaments, which cause elevation of the tail of the eyebrow.
Ck1	Under	Myomodulation on the zygomaticus major muscle and tension of the zygomatic-cutaneous-orbicular and orbicular true retaining ligaments, with canthopexy effect.
Ck2	Under	Myomodulation on the zygomaticus minor, orbicular, and levator upper lip muscles and tightening of the zygomatic-cutaneous-orbicular and orbital-malar true retaining ligaments, causing a canthopexy effect
Ck3	Undera	Myomodulation on the zygomaticus minor and levator upper lip muscles, and tightening of the zygomatic-cutaneous-orbicular and orbital-malar true retaining ligaments, which cause anterior/superior projection of the cheekbone.
Ck4	Above	Myomodulation on zygomaticus major muscle and tightening of true orbicularis retaining ligament.
O1	Under	Myomodulation on orbicular muscle and tightening of true orbicularis retaining ligament.
O2	Under	Myomodulation on orbicular muscle and tightening of true orbicularis retaining ligament.
O3	Under	Myomodulation on orbicular muscle and tightening of true orbicularis retaining ligament.
Tt1b	Underc	Myomodulation on orbicular muscle.
Tt2b	Underc	Myomodulation on orbicular muscle.
Tt3b	Underc	Myomodulation on orbicular muscle.

Notes: ^aInto the deep and supraperiosteal fat compartment at the medial level of the malar. ^bThe direct approach to this area is indicated when patients present negative snap-tests and have a normal or excessive suborbicularis oculi fat pad (SOOF) volume. ^cBolus of hyaluronic acid filler in front of the orbital septum, at supraperiosteal level, between the orbicularis retaining ligament and the zygomatic cutaneous ligament. Data from these studies.^10–12

Abbreviations: T1, anterior temple; T2, posterior temple; Ck1, zygomatic arch; Ck2, zygomatic eminence; Ck3, anteromedial cheek; Ck4, lateral lower cheek/parotid area; O1, central lateral orbital; O2, lower lateral orbital; O3, upper lateral orbital; Tt1, central infraorbital; Tt2, lateral infraorbital; Tt3, medial infraorbital.

Table 4 summarizes different HA injectable fillers used for the aesthetic management of the TTD in this article.

Table 4.

Overview of the Different Hyaluronic Acid (HA) Fillers Used in Tear Trough Deformity Treatment and Their Main Characteristics

	VYC-25L*	VYC-20L*	VYC-17.5L*	VYC-15L*	VYC-12L*
Indication	Restore and create volume of the face.	Facial volume restoration.	Treatment of deep skin depressions, face contouring and volume restoration to correct facial structural defects, contour deformities volume loss in the lips, cheeks, chin, lower face.	Treatment of fine lines and medium-sized skin depressions, enhancement and pouting of the lips to correct structural defects, contour deformities and volume loss.	Treatment of superficial cutaneous depressions such as fine lines and for improvement of skin quality attributes such as hydration and elasticity.
Concentration of HA	25 mg/mL	20 mg/mL	17.5 mg/mL	15 mg/mL	12 mg/mL
HA molecular weight	Low & high	Low & high	Low & high	Low & high	Low & high
Duration	Up to18 months	Up 2 years	Up to 18 months	Up 1 year	Up to 9 months

Note: *With lidocaine.

Abbreviations: VYC-25L, Volux^® (Allergan plc, Dublin, Ireland); VYC-20L, Voluma^® (Allergan plc, Dublin, Ireland); VYC-17.5L, Volif^® (Allergan plc, Dublin, Ireland); Volbella^® (Allergan plc, Dublin, Ireland); VYC-12L, Volite^® (Allergan plc, Dublin, Ireland); HA, hyaluronic acid.

Therapeutic Strategy

TTD treatment should not be restricted to the groove itself. It would be advisable to contemplate a comprehensive approach of the problem, which includes potential lack of structural support, as well as interventions on the dynamic processes involved in the problem.

Based on Hirmand,⁵ Belhaouari⁷ classifications, and facial lipoatrophy,¹³ we attempt to do a comprehensive approach for treating TTD that may help clinicians to treat this challenging area.

Table 5 shows different recommendations of the authors.

Table 5.

Authors Recommendations for Treating Tear Trough

Recommendations

● Make the injection with the patient seated as the tear trough deformity is better visualized in this position than when the patient is lying down. ● Use low-viscosity instead of high-viscosity hyaluronic acid (HA) or non-biodegradable agents, as it can be safely injected with fewer adverse effects. ● Avoid superficial injections to prevent the Tyndall effect, a bluish discoloration under the skin that may arise when the HA is injected too superficially. ● The HA filler should be gently massaged for even distribution, yet avoiding massaging too strongly. ● Follow the key principle “less is more”, in order to prevent bulges under the eye, it is much better to undercorrect rather than overcorrect the tear trough area. ● It is essential to be cautious while injecting around the infraorbital foramen to avoid injury to the neurovascular bundle. ● Inject very slowly. ● Both a needle or a cannula can be used with good results. Nevertheless, blunt-tipped cannulas may be safer due to the reduced chance of damaging vessels and nerves. ● The patients must be informed that they ought to avoid any strong or extended pressure to the area treated.

A proper diagnosis of the TTD is essential to address the right treatment strategy.

From a clinical point of view, the recommended therapeutic strategy of the tear trough deformity would be (Table 6):

• Direct approach (stages 2A and 3A of the Belhaouari classification system): Central infraorbital (Tt1) + Lateral infraorbital (Tt2) + medial infraorbital (Tt3) (Figure 3).

• Indirect approach (stages 1A,1B, 2B, and 3B of the Belhaouari classification system): Anterior temple (T1) + Zygomatic arch (Ck1) + Zygomatic eminence (Ck2) + Anteromedial cheek (Ck3) + Lateral lower cheek/parotid area (Ck4) + Submalar/buccal area (Ck5) + Tt1 + Tt2 + Tt3 + Central lateral orbital (O1) + Lower lateral orbital (O2) + Upper lateral orbital (O3) (Figure 4).

Table 6.

Overview of the Authors’ Recommendations for Treating Tear Trough Deformity with Hyaluronic Acid (HA) Filler According to the MD Codes^®.

Code	HA Filler	Amount	Administration	Level
T1+T2	VYC-20L/VYC-25L	0.5 to 0.7 mL	27G needle	Supraperiosteal
Ck1a	VYC-20L/VYC-25L	0.3 mL	27–30 needle	Supraperiosteal
Ck2	VYC-20L	0.1 to 0.2 mL	27–30G needle	Supraperiosteal
Ck3b	VYC-20L	0.2 to 0.4 mL	27G and 30G needle	Supraperiosteal
	VYC-20L+VYC-17.5L	0.3 to 0.6 mL	25G-27G blunt cannula	Supraperiosteal
Ck4	VYC-20L	0.5 to 0.7 mL	25–27 G blunt cannula	Deep subcutaneous
Ck5	VYC-20L or VYC-25Lc	0.4 to 0.7 mL	25–27 G blunt cannula	Deep subcutaneous
O1d	VYC-15L or VYC-20L	0.1–0.15 mL	27–30G needle	Supreperiosteal
O2d	VYC-15L or VYC-20L	0.1–0.15 mL	27–30G needle	Supreperiosteal
O3d	VYC-15L or VYC-20L	0.1–0.15 mL	27–30G needle	Supreperiosteal
Tt1	VYC-15L	0.1–0.2 mL	27 G blunt cannula	Supreperiosteal
Tt2	VYC-15L	0.1–0.2 mL	27 G blunt cannula	Supreperiosteal
Tt3	VYC-15L	0.1–0.1 mL	27 G blunt cannula	Supreperiosteal

Notes: ^aIt is possible to inject 3 microboluses of 0.1 mL (one in the suture notch and the other two ones to the sides). ^bTreatment is performed in two phases. Phase 1: To inject 0.2 to 0.4 mL of a HA filler of 20 mg/mL (VYC-20L), at the supraperiosteal, by means 27G and 30G needles. Phase 2: Injecting 0.3 to 0.6 mL (with a fan technique) of VYC-20L, by means25-27G cannulas, and injecting afterwards in the same area a more superficial amount of HA (either VYC-25L or VYC-20L, according to the patient needs) under the orbicularis muscle. ^cThe injection of the bolus of VYC-20L or VYC-25L depends on the skin thickness and bone structure of the patient. ^dIn some patients with excessive contractility of the orbicularis muscle, it is necessary to inject, at the superficial subdermal level, a HA filler (VYC-15L) for correcting the horizontal wrinkles. Data from these studies.^10–12

Abbreviations: T1, anterior temple; T2, posterior temple; Ck1, zygomatic arch; Ck2, zygomatic eminence; Ck3, anteromedial cheek; O1, central lateral orbital; O2, lower lateral orbital; O3, upper lateral orbital; Tt1, central infraorbital; Tt2, lateral infraorbital; Tt3, medial infraorbital; VYC-15L, Volift^® (Allergan plc, Dublin, Ireland); VYC-17.5L, Volbella^® (Allergan plc, Dublin, Ireland); VYC-20L, Voluma^® (Allergan plc, Dublin, Ireland); VYC-25L, Volux^® (Allergan plc, Dublin, Ireland).

Figure 3.

Overview of the different codes involved in the tear trough deformity direct approach treatment. Image courtesy from and reprinted with permission from Allergan plc, Dublin, Ireland. Codes have been adapted from de Maio.^10,11

Abbreviations: Tt1, central infraorbital; Tt2, lateral infraorbital; Tt3, medial infraorbital.

Figure 4.

Overview of the different Codes involved in the tear trough deformity indirect approach treatment. Data from Peng et al⁶ and de Maio.¹⁰ Image courtesy from and reprinted with permission from Allergan plc, Dublin, Ireland.

Abbreviations: Ck1, zygomatic arch; Ck2, zygomatic eminence; Ck3, anteromedial cheek; Ck4, lateral lower cheek/parotid area; Ck5, submalar/buccal area; O1, central lateral orbital; O2, lower lateral orbital; O3, upper lateral orbital.

Figures 3 and 4 summarize the different treatment strategies.

Results

Direct Approach

The proper technique for a direct approach of tear trough area and palpebro-malar area is to use HA fillers of mid to low density, elasticity, and cohesiveness, and additionally, with a mid to low water retention capacity. HA should be administered in small boluses with a 25/27 G blunt cannula, performing always an aspiration maneuver before injecting the filler^6,10,11 (Figure 5).

Figure 5.

Codes involved in the direct approach strategy for treating tear trough deformity. Tear trough and orbital codes should be reserved for specialists specifically trained in this technique and those who have a sound knowledge of the anatomy and physiology for this particular area. Data from Peng et al⁶ and de Maio.¹⁰ Image courtesy from and reprinted with permission from Allergan plc, Dublin, Ireland. (A) Imaging representing the frontal view. (B) Imaging representing the anatomical structures. Red circle under Tt1 and exclamation mark: Be aware of the infraorbital artery branches. Red circle near to Tt3 and exclamation mark: Be aware of the angular artery and vein. Codes have been adapted from de Maio.^10,11

Abbreviations: Tt1, central infraorbital; Tt2, lateral infraorbital; Tt3, medial infraorbital.

The direct approach to this area is indicated when patients present negative snap-tests and have a normal or excessive suborbicularis oculi fat pad (SOOF) volume. In other words, those subjects classified as stages 2 and 3 in the Belhaouari classification or Class I in the Hirmand one (Figure 1 and Table 2).

The treatment approach consists in a bolus of HA filler in front of the orbital septum (a thin fibrous layer arising from the periosteum along the inferior and superior orbital rims), at supraperiosteal level, between the orbicularis retaining ligament and the zygomatic cutaneous ligament^6,11 (Figure 5).

The specialist must be aware of the infraorbital artery branches and of the angular artery and vein. It is important to take into account that tear trough and orbital codes should be reserved for well-trained and experienced specialists, who had received specific training in this technique and those who have an exhaustive knowledge of the anatomy and physiology for this particular area.^10,11

Indirect Approach

This treatment strategy is based on the sequence: Structure-Contour-Refinement.

Structure

Temporal Region

The point that should be treated is T1, at the supraperiosteal level, accessing from T1 located at the fronto-sphenoidal junction, at the beginning of the temporal fossa (Figure 6).

Figure 6.

Temporal point to be treated. Data from de Maio.¹⁰ Image courtesy from and reprinted with permission from Allergan plc, Dublin, Ireland.

Abbreviation: T1, anterior temple.

A HA filler presenting a G’ and high cohesivity, such as VYC-25L (Volux^®; Allergan plc, Dublin, Ireland) or VYC 20L (Voluma^®; Allergan plc, Dublin, Ireland), in thin skins, may be used. Injection is made by using with a 27G needle, performing a supraperiosteal bolus of approximately 0.5–0.7 mL. A soft massage, for redistributing the product, is subsequently done.

The clinical effect obtained is the correction of the temporal fossa, at the supraperiosteal level and below the temporal muscle, with elevation of the eyebrow tail, which causes tension in orbicular muscle.

Special attention should be paid to the temporal arteries, which are located at the posterior supraperiosteal level, below the temporal muscle. HA filler injection at point T1 should be located anterior to the vessels. The location of point T1 at the level of the fronto-sphenoidal junction is performed by asking the patient to open the mouth. Before injecting, aspiration should be performed as a prophylactic measure and a new needle without filler should be used prior to deep bolus injections.^14,15

Cheek Region

In some cases, TTD may be addressed by treating the lateral cheek.

Three different points: Ck1, Ck2, and Ck3 are treated (see Figure 7).

Figure 7.

Structural treatment of tear trough deformity. Image courtesy from and reprinted with permission from Allergan plc, Dublin, Ireland. ^aDo not inject into the cartilage or into the bone, but rather at the level of the cartilage or the level of the bone.

Abbreviations: Ck, cheek; Ck1, zygomatic arch; Ck2, zygomatic eminence; Ck3, anteromedial cheek.

For treating Ck1, a 27 needle, at supraperiosteal level, should be used. A HA filler, like VYC-20L or VYC-25L, in a 0.3 mL bolus or 3 microboluses of 0.1 mL (one in the suture notch and the other two ones to the sides). The 3 microboluses approach provides greater tension than the 0.3 mL bolus one.

The clinical effect of this Code would be tension at the supraperiosteal level of the zygomaticus major muscle, orbicular and zygomaticus-cutaneous-orbicular retaining ligaments (with canthopexy effect), and myomodulation of the zygomaticus major and orbicularis muscles.

Therapeutic approach of Ck2 point is made at supraperiosteal level by means a 27G needle, applying a 0.1–0.2 mL bolus of a HA filler (VYC-20L) (Figure 7).

We should be aware of the zygomaticofacial artery. At this point, aspiration is highly recommended before injecting the filler.¹⁰

The clinical effect on this point would be tautness the muscles zygomaticus minor and levator labii superioris. Additionally, it tightens the zygomatic-cutaneous-orbicularis and the orbitomalar retaining ligaments (with canthopexy effect), as well as myomodulation of the zygomaticus minor, orbicularis, and lip levator muscles inducing latero-facial tension.^10,11

Ck3 treatment should be done before treating the nasojugal groove.⁶ Its treatment can be performed with 25G blunt cannula and with 27G needle.

The treatment of this point is carried out in two phases. The first one is to inject 0.2 mL to 0.4 mL of a HA filler of 20 mg/mL (VYC-20L), at the supraperiosteal level and performing aspiration before injecting the filler. Subsequently, through the same point, we will access to the deep-medial inferior SOOF, by means a 25/27G blunt cannula, first at the supraperiosteal level, injecting 0.3 to 0.6 mL (with a fan technique) of VYC-20L, and injecting afterwards in the same area a more superficial amount of HA either VYC-17.5L (Volbella^®; Allergan plc, Dublin, Ireland) or VYC-20L, according to the patient needs, under the orbicularis muscle.^6,10

Injection of VYC-20L or VYC-17.5L depends on the skin thickness and bone structure of the patient. It is important to bear in mind that injecting HA fillers superficially, above the orbicularis muscle, without having provided previously structure to the deep ones, may cause a “squirrel” appearance, which will be increased with facial mimicry.^16,17

Treatment of this point would induce tautness by increasing volume, at supraperiosteal level, of the zygomaticus minor and levator labii superioris muscles and the zygomatic-cutaneous-orbicularis and orbitomalar retaining ligaments, which cause anterosuperior projection of the cheekbone. Additionally, the treatment of the Ck3 point induces muscle myomodulation of the zygomaticus minor, orbicularis, and levator labii superioris muscles.

Specialists should be aware of the infraorbital neurovascular bundle, which emerges onto the face through the infraorbital foramen. It is located above the zygomatic process of the maxilla, about 2–3 cm from the median vertical line of the face. Therefore, aspiration is highly recommended when injecting a HA filler at this point.^6,10,11

If nasojugal sulcus needs to be treated, the SOOF approach is crucial. Figure 8 shows an overview of different anatomical structures and the Codes of the periorbital region.

Figure 8.

Different anatomical structures and the codes of the periorbital region. Data from de Maio.¹⁰ Image courtesy from and reprinted with permission from Allergan plc, Dublin, Ireland.

Abbreviations: E1, eyebrow tail; E2, eyebrow center; E3, eyebrow head; T1, anterior temple; T2, posterior temple; Ck1, zygomatic arch; Ck2, zygomatic eminence; Ck3, anteromedial cheek; Ck4, lateral lower cheek/parotid area; Tt1, central infraorbital; Tt2, lateral infraorbital; Tt3, medial infraorbital.

Contour

Once the treatment of facial structure has been addressed, the second step is to reestablish those facial contours that were lost throughout the facial aging process.

The therapeutic approach of the contours requires special actions on certain static and dynamic facial Codes that, in turn, are based on the structure management performed during the first phase of the treatment.

Once the structural codes at the cheekbones, Ck1, Ck2, and Ck3 have been addressed (see Structure section), it is time to integrate the “structural anatomical corrections” into a comprehensive approach more visual and understandable for the patients (Figure 4).

Treatment is usually performed with a 25–27 G blunt cannula, with a fan technique, by using a 20 mg/mL HA filler (VYC-20L). Special attention should be paid to the small preauricular and superficial zygomatic vessels, which are frequent in this region.^6,10,18

Therapeutic approach to Ck5 Code is subcutaneous, with either VYC-25L or VYC-20L (in patients with thin skin), by means a 25–27G blunt cannula, with a fan technique, from the oral commissure and upwards towards Ck4.^6,10 The amount of filler ranges from 0.4 mL to 0.7 mL depending on patient’s needs. The clinical effect is to provide volume to a lipoatrophic area that becomes evident when the patient sucks or pouts their lips. The HA is injected deep subcutaneous, above the buccinator muscle and under the risorius one, inducing myomodulation in both muscles.^6,11

The management of these Codes will provide a more contoured appearance of the cheek region, without “steps” in the zygomatic arch area, trying to integrate the restored/created structure in the facial contour. In men, it is advisable to reinforce the anterior projection of the cheek bone a little bit more. Whereas, in women, the posterior anterolateral projection will determine the beauty.

Refinement

Refinement is the third step of this comprehensive therapeutic approach and represents its “final touch”, once the structure and contour processes have been carried out.

Orbicular Region

The main purpose of volumizing this area is to recover the supraperiosteal deep fat pockets, which, along with loss of the orbital bone rim, determine the subcutaneous structure of the lateral orbit (Figure 4).

In many patients, TTD causes sagging and superficial dynamic wrinkles due to both a hypercontractility of the orbicularis muscles and a laxity of the orbicular retaining ligament.

The treatment is performed, by administering a supraperiosteal bolus (0.1–0.15mL, at each point O1, O2, O3), of a 15 mg/mL HA filler (VYC-15L; Volift ^®; Allergan plc, Dublin, Ireland), by means a 30G needle.^6,10,11 The objective is to induce myomodulation of the orbicularis muscle and increase the tension of the orbicular retaining ligament, causing a slight canthopexy effect and correcting horizontal wrinkles.

Clinical results, assessed by means photographs, have shown a significant aesthetic improvement (Figures 9 and 10).

Figure 9.

Frontal, right, and left projection of a 40-year-old patient face before (A) and after (B) being treated. The patient provided their consent for the use of their image in this publication. 1. Zygomatic arch (Ck1): 0.3 mL per side of Hyaluronic acid filler (VYC-20L). 2. Anteromedial cheek (Ck3): 0.7 mL per side of Hyaluronic acid filler (VYC-20L). Image courtesy with permission from Dr Farollch. Codes have been adapted from de Maio.¹⁰

Figure 10.

Forty-five years old women with a tear trough deformity (according to Belhaouari classification: 1B (see reference 7)) before treatment (A); that shows the treatment plan (B); and after treatment (C). The patient provided their consent for the use of their image in this publication. 1. Temporo-orbicular cutaneous retaining ligament; 2. Anterior temple (T1); 3. Palpebral ligament; 4. Orbicular retaining ligament; 5. Zygomatic-cutaneous-orbicularis retaining ligament; 6. Zygomatic arch (Ck1); 7. Zygomatic eminence (Ck2); 8. Anteromedial cheek (Ck3); 9. Central infraorbital (Tt1); 10. Medial infraorbital (Tt3). T1 (2): 0.5 mL per side of Hyaluronic acid (HA) filler (VYC-25L; Volux^®; Allergan plc, Dublin, Ireland). Ck1 (6): 3 microboluses of 0.1 mL (one in the suture notch and the other two ones to the sides) of HA filler (VYC-20L). Ck2 (7): 0.1 mL of HA filler (VYC-20L). Ck3 (8): 0.2 mL lateral + 0.25 mL medial of HA filler (VYC-20L). Tt1 (9): 0.2 mL of HA filler (VYC-20L). Tt3 (10): 0.2 mL of HA filler (VYC-20L). Image courtesy with permission from courtesy of Dr Urdiales-Gálvez. Codes have been adapted from de Maio.¹⁰

There are some Codes that merit a special consideration (Table 7).

Table 7.

Different Aspects That Need to Be Considered When Injecting Hyaluronic Acid (HA) Fillers for Treating Tear Trough Deformity. Adapted from de Maio

MD Code®	Special Consideration
T1	Pay attention to the superficial frontal artery and the deep temporal arteries.
Ck1	None
Ck2	Pay attention to the zygomaticofacial artery
Ck3	Pay attention to the infraorbital artery
Tt1	Pay attention to the infraorbital artery branches
Tt2	None
Tt3	Pay attention to the angular artery and vein

Note:Data from these studies.^10,11

Abbreviations: T1, anterior temple; Ck1, zygomatic arch; Ck2, zygomatic eminence; Ck3, anteromedial cheek; Tt1, central infraorbital; Tt2, lateral infraorbital; Tt3, medial infraorbital.

As previously mentioned, aspiration is highly recommended when performing injections at a deep level. Additionally, the TTD treatment should be performed only by well-trained and experienced specialists, who have a sound knowledge of the anatomy of this region.^10,11

Safety

Adverse events can be divided into early events (occurring up to several days post-treatment) or delayed events (occurring from weeks to years post-treatment). Early events include pain, erythema, etc., while delayed events include orange-brown staining, Tyndall effect, etc.^19–23 (Tables 8 and 9).

Table 8.

Overview of the Adverse Events Associated with the Use of Dermal Fillers. Adapted from Funt and Pavicic

	Early Adverse Eventsa	Delayed Adverse Eventsb
Injection site reactionsc	Erythema Edema Pain/tenderness Bruising Itching	Erythema Edema Pain/tenderness Nodule/abscess Systemic responses Biofilm
Infection	Erythema Edema Pain/tenderness Acne papule formation Nodule/abscess	Foreign body granulomad
Hypersensitivity	Erythema Edema Pain/tenderness Non-fluctuant nodules	Migration of filler material
Technical and placement errors	Lumps Asymmetries Contour irregularities Dysesthesias, paresthesias, and anesthesia	Immune reactions Dysesthesias, paresthesias, and anesthesia
Skin discoloration	Redness Whiteness Hyperpigmentation	Persistent discoloration Persistent scarring
Vascular compromisee	Blurred vision Loss of vision	Tissue necrosis

Notes: ^aOccurring up to several days post-treatment. ^bOccurring from weeks to years post-treatment. ^cAtypical as delayed adverse events. ^dVarying from subclinical histologic changes to disfiguring nodules. ^eRetinal artery occlusion. Data from these studies.^19-21,23

Table 9.

Overview of the Early and Delayed Adverse Events in Patients Who Underwent Tear Trough Deformity Treatment with Hyaluronic Acid (HA) Fillers

Early Adverse Events
Event	Prevention/Treatment
Pain	To use HA fillers with lidocaine
Erythema	N.A.
Swelling/Bruising	To avoid all blood-thinning medications. Fillers that incorporate lidocaine and epinephrine (adrenaline) may reduce the amount of postinjection bruising. To apply firm pressure and ice packs before and after the treatment session.
Asymmetry	N.A.
Migraine	N.A.
Delayed Adverse Events
Event	Prevention/Treatment
Orange-brown staining	Preinjection ice application. Proper depth of injection. Discontinuation of anticoagulants at least seven days before injection.
Postinflammatory hyperpigmentation	It is usually associated with dark skin types due to bruising and hematoma. It can be difficult to treat
Puffiness	Its incidence may be reduced by proper patient and filler selection.
Infections	Filler injections should not be performed if there is an infection in the adjacent site. It can be treated with antibiotics active against frequent skin bacteria including Staphylococcus epidermidis or Propionibacterium acnes.
The Tyndall effect	It occurs when particulate HA fillers are inappropriately implanted into the superficial dermis or epidermis. Hyaluronidase should be the initial approach to treatment.
Nodules	They can be treated with local massage, aspiration or incision and drainage of the product. Hyaluronidase can be used to dissolve a nodule or a focus of overcorrection.
Blindnessa	To limit the amount of filler bolus injected in one site. One way to do this is to use blunt cannulas. To apply minimal pressure on the syringe, which decreases the risk of retrograde flow into the retinal arteries.

Notes: Data from these studies.^15,19-23 aRetinal artery occlusion is a rare event.²⁴

Abbreviations: HA, hyaluronic acid; NA, not applicable.

More serious and true complications with fillers include vascular occlusion and necrosis.^19–25 In the authors’ practice, no serious complications, such as arterial embolic accident or necrosis, have occurred.

Discussion

Since facial aging involves interactions between changes in various anatomic structures (bone, ligaments, muscles, adipose tissue, and skin),³ knowledge of age-related anatomy changes is, therefore, crucial for achieving elegant and aesthetically balanced results.

Tear trough deformity is one of the most challenging areas in facial rejuvenation, which requires a comprehensive treatment approach for addressing the different age-related changes that occur at that level.¹⁸ In younger people TTD is mainly restricted to the tear trough. However, during aging TTD may affect the entire region under the eye.

Many different strategies have been used for addressing TTD treatment. Nevertheless, there is growing interest in techniques that provide a tailored approach towards specific anatomic abnormalities.

Despite HA fillers have been successfully used for correcting periorbital volume loss, their role in addressing TTD combined with eye bags is a relatively new practice. It has been reported that HA fillers may be a valuable option for treating not only periorbital hollowness but also concealed the bulge of infraorbital fat pads.^18,26 Additionally, it was recently proposed a treatment strategy with HA fillers that had into consideration different anatomic aspects of TTD.²⁷

We propose two patient-tailored treatment approaches, according to their facial structure. Both, direct and indirect treatment approaches, are based on the Codes.¹⁰

Direct approach is mainly focus in volumizing tear trough and palpebromalar areas (stages 2A and 3A of the Belhaouari classification system and Class I in the Hirmand one). It is indicated in patients who present negative snap-tests and have a normal or excessive SOOF volume.

The indirect approach is indicated in those cases who require a comprehensive strategy and is based on the sequence: Structure-Contour-Refinement.

Regarding structure, therapeutic strategies should be focused on providing an adequate correction of the age-related structure loss.

When thinking about contour, it is essential to take into consideration the sexual dimorphism in human facial form, which involves both size and shape variations of the soft tissue structures.²⁸ These contours will require special actions on certain facial areas.¹⁰ However, it should be considered that previous actions on structure could have been done, which might have already modified the facial contour.

Once the structure and contours have been restored, refinement represents the “final touch” of the treatment. At this time, those “details” that were not corrected when treating structure and contour should be addressed. A proper correction of the small details is going to have a great impact on the aesthetic outcomes and patient satisfaction, even greater than those achieved with the structural or contouring approach.¹¹

Structure, contour, and refinement have different Codes assigned to each of them, which will facilitate the systematization of the treatment approaches throughout the process.

The Codes represents precise anatomical sites and procedures for the injection of HA fillers, which might easily serve as a platform of communication for clinicians worldwide.¹⁰

The Codes were designed to address aging changes that are visible at rest.¹⁰ Their purpose is to improve structure, contour, and refinement.

On the other hand, the MD Dyna Codes^® were designed to address dynamic aging changes by mechanical modulation of the muscle and providing a natural appearance during muscle activity.¹¹

The lack or the loss of structural support can yield alterations in facial muscles, which affects the balance in activity between them.^11,12 HA filler treatment may be used to modulate muscle activity, either supporting its movement or reducing its overaction, regardless unbalance is due to a structural deficiency or a loss of volume in aging.^11,12 Mechanical myomodulation refers to the effect that the HA fillers have on the function of facial mimetic muscles.^11,12

Codes of the upper and midface are involved in the treatment of the TTD.^29,30

A proper selection of HA filler is a crucial point of these treatment approaches. Different manufacturing-related factors, including HA concentration, polymer chain length, crosslinking degree, or cross-linking technology are going to influence significantly on different filler properties, such as requisite needle size; particle size; duration; extrusion force; and elastic Modulus (G’), which will critically influence product selection and indication.^31–33 For example, VYC-25L, VYC-20L, and VYC-17.5L, for their rheologic characteristics, are specially indicated for addressing structural deficiencies,²⁷ whereas VYC-15L is more indicated for refining.^26,27

Regarding safety, as indications for HA fillers expand, the number and spectrum of adverse events will increase. Most adverse events of HA fillers are mild and transient. However, more serious adverse events can occur, leaving patients with long-lasting or permanent functional and aesthetic defects.^{15,19–21,23}

Correction of a TTD with nonsurgical techniques presents unique challenges. Unlike other facial hollows (such as the nasolabial folds, which are easily camouflaged), the tear trough requires more technically demanding treatment due to the breadth of the hollow, skin quality changes (thinning), and the presence of adjacent orbital fat pads.^2,14

As limitation, need to be mentioned that the current article presents the personal experience of the authors on a specific subject and this fact should be considered when interpreting data from this paper. Additionally, all the treatments have been done with Vycross^® technology products. Appropriate caution is therefore recommended when extending the results to other HA fillers.

Conclusions

The treatment of TTD should be addressed from a comprehensive perspective, including potential lack of structural support, as well as interventions on the dynamic processes involved in the problem.

Additionally, it should be taken into consideration that TTD was listed as the most challenging area to treat with HA. That is why TTD treatment should be performed only by well-trained and experienced specialists, who have a sound knowledge of the anatomy of this region.

Funding Statement

Medical writing services has been provided by Allergan Aesthetics, an AbbVie company. Allergan did not participate in either data collection, analysis or redaction of the manuscript. Neither honoraria nor payments were made for authorship.

Author Contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Disclosure

Dr Urdiales-Gálvez has received a grant from Allergan Aesthetics, an AbbVie company, for covering the medical writing services. Dr Farollch-Prats has received research grants from Allergan Aesthetics, an AbbVie company.